Cipla is currently trading at Rs. 597.00, up by 11.70 points or 2.00% from its previous closing of Rs. 585.30 on the BSE.
The scrip opened at Rs. 590.00 and has touched a high and low of Rs. 604.85 and Rs. 587.65 respectively. So far 1,19,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 639.05 on 16-Sep-2014 and a 52 week low of Rs. 366.70 on 24-Feb-2014.
Last one week high and low of the scrip stood at Rs. 629.70 and Rs. 579.10 respectively. The current market cap of the company is Rs. 47,934.00 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 35.85% and 26.23% respectively
Cipla’s step-down subsidiary - Medpro Pharmaceutica has entered into collaboration with Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries (Teva) - the largest generic pharmaceutical manufacturer in the world with a presence in about 60 countries and approximately 45,000 dedicated employees worldwide. Medpro Pharmaceutica is a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa.
The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva’s broad pharmaceutical product portfolio in South Africa. The collaboration is restricted to the territory of South Africa and is subjected to approval by the Competition Commission of South Africa.
The collaboration with Teva in South Africa will focus on the following therapeutic areas: oncology, central nervous system, women's health, cardiovascular, ophthalmology and other specialty products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: